deltatrials
Terminated PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT03225924

Study of Entospletinib (ENTO) in Newly Diagnosed DLBCL Patients With aaIPI>=1 Treated by Chemiotherapy

Phase Ib - II Study of Entospletinib (ENTO) in Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL) Patients With aaIPI>=1 Treated by Rituximab, Cyclophosphamide, Hydroxydaunomycin, Oncovin, and Prednisone (R-CHOP)

Sponsor: The Lymphoma Academic Research Organisation

Conditions DLBCL
Interventions Cyclophosphamide Doxorubicin Entospletinib Prednisone Rituximab Vincristine
Updated 12 times since 2017 Last updated: Sep 1, 2020 Started: Jul 26, 2017 Primary completion: Oct 18, 2019 Completion: Oct 18, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Stop of drug development

Other terminated trials from The Lymphoma Academic Research Organisation

See all terminations from The Lymphoma Academic Research Organisation

Other DLBCL trials with similar outcome

Browse all DLBCL trials

This PHASE1/PHASE2 trial investigates DLBCL and is currently terminated or withdrawn. The Lymphoma Academic Research Organisation leads this study, which shows 12 recorded versions since 2017 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Aug 2017 – ~Sep 2017 · 31 days · monthly snapshotRecruiting~Sep 2017 – ~Jun 2018 · 9 months · monthly snapshotRecruiting~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshotRecruiting~Sep 2018 – ~Dec 2018 · 3 months · monthly snapshotRecruiting~Dec 2018 – ~Jun 2019 · 6 months · monthly snapshotRecruiting~Jun 2019 – ~Aug 2020 · 14 months · monthly snapshotActive Not Recruiting~Aug 2020 – ~Oct 2020 · 2 months · monthly snapshotTerminated~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshotTerminated~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotTerminated~Sep 2025 – present · 10 months · monthly snapshotTerminated

Change History

12 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE1/PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE1/PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  4. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE1_PHASE2

  5. Oct 2020 — Jan 2021 [monthly]

    Terminated PHASE1_PHASE2

▶ Show 7 earlier versions

  1. Aug 2020 — Oct 2020 [monthly]

    Terminated PHASE1_PHASE2

    Status: Active Not Recruiting → Terminated

  2. Jun 2019 — Aug 2020 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  3. Dec 2018 — Jun 2019 [monthly]

    Recruiting PHASE1_PHASE2

  4. Sep 2018 — Dec 2018 [monthly]

    Recruiting PHASE1_PHASE2

  5. Jun 2018 — Sep 2018 [monthly]

    Recruiting PHASE1_PHASE2

  6. Sep 2017 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

  7. Aug 2017 — Sep 2017 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Jul 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • The Lymphoma Academic Research Organisation
Data source: The Lymphoma Academic Research Organisation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bourg-en-Bresse, France , Brussels, Belgium , Caen, France , Créteil, France , Dijon, France , Ghent, Belgium , Haine-Saint-Paul, Belgium , Kortrijk, Belgium , Le Chesnay, France , Le Mans, France and 15 more locations